IN8bio Announces INB-200 Phase 1 Data Update In Glioblastoma At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio announced that 100% of treated patients in the INB-200 Phase 1 study for glioblastoma have exceeded historical median progression-free survival. The company is on track to complete enrollment in 2023 with updated data expected later this year.
June 05, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's INB-200 Phase 1 study shows promising results in glioblastoma treatment, with all treated patients exceeding historical median progression-free survival.
The positive results from IN8bio's INB-200 Phase 1 study indicate a potential breakthrough in glioblastoma treatment. This news is highly relevant to INAB as it directly pertains to their product pipeline and could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100